Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.625
-0.002 (-0.30%)
At close: Nov 20, 2024, 4:00 PM
0.620
-0.005 (-0.83%)
After-hours: Nov 20, 2024, 6:48 PM EST
Veru Inc. Employees
Veru Inc. had 189 employees as of September 30, 2023. The number of employees decreased by 44 or -18.88% compared to the previous year.
Employees
189
Change (1Y)
-44
Growth (1Y)
-18.88%
Revenue / Employee
$74,560
Profits / Employee
-$197,899
Market Cap
91.53M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| MultiPlan | 2,800 |
| Inotiv | 2,055 |
| So-Young International | 1,357 |
| 23andMe Holding Co. | 582 |
| Harvard Bioscience | 416 |
| Allakos | 131 |
| Invivyd | 95 |
| Regulus Therapeutics | 30 |
VERU News
- 15 days ago - Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek - GlobeNewsWire
- 4 weeks ago - Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss - GlobeNewsWire
- 5 weeks ago - Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress - GlobeNewsWire
- 2 months ago - Veru to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Veru Inc. (VERU) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results - GlobeNewsWire
- 3 months ago - Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024 - GlobeNewsWire
- 4 months ago - Veru to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire